Physician profile
Jay B Winston
NPI 1164580015
$237,631.71
in general payments reported to CMS, 2019-2025
34 companies · $51K in 2025
The $51K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $14K · 2021: $32K · 2022: $12K · 2023: $42K · 2024: $46K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Honoraria: $22K · Travel and Lodging: $15K · Food and Beverage: $13K · Consulting Fee: $3,680 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,838.38 |
| Honoraria | $21,850.00 |
| Travel and Lodging | $14,629.65 |
| Food and Beverage | $12,962.45 |
| Consulting Fee | $3,680.00 |
| Education | $419.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $143,715.28 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $62,626.10 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $15,617.34 | 2022-2025 | Azstarys |
| Lundbeck LLC | $2,445.78 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $2,383.69 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $1,704.43 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $901.63 | 2021-2025 | Vraylar |
| Neos Therapeutics, LP | $861.67 | 2019-2025 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $701.09 | 2020-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $656.99 | 2019-2023 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $646.73 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $571.21 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $505.78 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $497.80 | 2021-2025 | Caplyta |
| Almatica Pharma LLC | $474.88 | 2022-2025 | Loreev Xr, Sertraline Hcl |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $385.63 | 2019-2020 | |
| Shire North American Group INC | $340.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $338.71 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $326.26 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $304.88 | 2023-2025 | Ingrezza |
| Tris Pharma INC | $255.13 | 2019-2025 | Dyanavel Xr |
| Harmony Biosciences LLC | $238.49 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $192.05 | 2025 | Jornay Pm |
| Eisai INC. | $157.24 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $152.22 | 2019-2022 | |
| Alkermes, INC. | $141.63 | 2022-2023 | Aristada, Vivitrol, Lybalvi |
| Owp Pharmaceuticals, INC. | $131.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $123.70 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $65.69 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $44.45 | 2019-2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $36.93 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $36.35 | 2025 | Cobenfy |
| Indivior INC. | $30.58 | 2024 | Perseris |
| Sage Therapeutics, LLC | $18.78 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Winston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.